By a News Reporter-Staff News Editor at Drug Week -- New research on Cancer Therapy is the subject of a report. According to news reporting originating in Leipzig, Germany, by NewsRx editors, the research stated, "Research on T helper 17 (Th17) cells with regard to immunoediting has revealed elusive results. Whereas enhanced Th17 response and related molecules such as interleukin (IL)-17, IL-21, IL-22, IL-23 and STAT3 accompanied tumor induction and progression, finding that tumor growth/stage was negatively correlated with increased infiltration of Th17 cells in the tumor mass has prompted elucidation of various antitumor mechanisms elicited by Th17 and their related molecules."
The news reporters obtained a quote from the research from Institute for Biochemistry, "The pro-tumor efficacy of Th17 response included promotion of neutrophilia and induction of angiogenic (e.g. VEGF, MMP2 and MMP9) and anti-apoptotic factors (e.g. Bcl-XL), as well as expansion and activation of myeloid-derived suppressor cells, which facilitate generation of tumor-specific regulatory T cells. Other tumor immunogenic settings revealed anti-tumor pathways including induction of cytotoxic activity, expression of MHC antigens, the ability Th17 cells to reside within the tumor, and to convert into IFN-gamma producers. Notably, Th17 cell related molecules exert indirect pro- or anti-tumor effects via inducing viral persistence or mediating protective mechanisms against bacterial and viral infection."
According to the news reporters, the research concluded: "Herein, the recent literature revealing such immunoediting events mediated by Th17 cells and their associated molecules as delivered by various experimental regimens and observed in cancer patient are revised, with a focus on some proposed anti-cancer therapies."
For more information on this research see: Anti-cancer versus cancer-promoting effects of the interleukin-17-producing T helper cells. Immunology Letters, 2013;149(1-2):123-133. Immunology Letters can be contacted at: Elsevier Science Bv, PO Box 211, 1000 Ae Amsterdam, Netherlands. (Elsevier - www.elsevier.com; Immunology Letters - www.elsevier.com/wps/product/cws_home/506020)
Our news correspondents report that additional information may be obtained by contacting N.Y.A. Hemdan, Fac Med, Inst Biochem, D-04103 Leipzig, Germany (see also Cancer Therapy).
Keywords for this news article include: Europe, Leipzig, Germany, Oncology, Peptides, Proteins, Cytokines, Cancer Therapy, Interleukin-17
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC
To see more of the NewsRx.com, or to subscribe, go to http://www.newsrx.com .